Best Practice & Research Clinical Rheumatology
Volume 20, Issue 6 , Pages 1181-1195 , December 2006

Bacterial and opportunistic infections during anti-TNF therapy

  • Joachim Listing, PhD (Senior Statistician)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49 30 28460 623; Fax: +49 30 28460 790.

References 

  1. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis and Rheumatism. 1994 Apr;37(4):481–494
  2. Thomas E, Symmons DP, Brewster DH, et al. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. The Journal of Rheumatology. 2003 May;30(5):958–965
  3. Sihvonen S, Korpela M, Laippala P, et al. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scandinavian Journal of Rheumatology. 2004;33(4):221–227
  4. Doran MF, Pond GR, Crowson CS, et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year-period. Arthritis and Rheumatism. 2002;46:625–631
  5. Stuck AE, Minder CE, Frey FJ. Risk of Infectious Complications in Patients Taking Glucocorticosteroids. Reviews of Infectious Diseases. 1989 Nov;11(6):954–963
  6. Gluck T, Kiefmann B, Grohmann M, et al. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. The Journal of Rheumatology. 2005 Aug;32(8):1473–1480
  7. Boerbooms AM, Kerstens PJ, van Loenhout JW, et al. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 1995 Jun;24(6):411–421
  8. Cunnane G, Doran M, Bresnihan B. Infections and biological therapy in rheumatoid arthritis. Best Practice and Research Clinical Rheumatology. 2003 Apr;17(2):345–363
  9. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls – A population-based study. Arthritis and Rheumatism. 2002 Sep;46(9):2287–2293
  10. Zochling J, Bohl-Buhler MH, Baraliakos X, et al. The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms. Clinical Rheumatology. 2006 Sep;25(5):648–658
  11. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis and Rheumatism. 1998;41:58–67
  12. Martinez A, Pacheco-Tena C, Vazquez-Mellado J, Burgos-Vargas R. Relationship between disease activity and infection in patients with spondyloarthropathies. Annals of the Rheumatic Diseases. 2004 Oct;63(10):1338–1340
  13. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis and Rheumatism. 2005 Oct 27;52(11):3403–3412
  14. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 May 17;295(19):2275–2285
  15. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism. 2004 Nov;50(11):3432–3443
  16. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk – A multicenter active-surveillance report. Arthritis and Rheumatism. 2003 Aug;48(8):2122–2127
  17. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism. 2006 Jun 26;54(7):2136–2146
  18. Davis JC, van der Heijde DM, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Annals of the Rheumatic Diseases. 2005 Nov;64(11):1557–1562
  19. Alarcon GS. Methotrexate use in rheumatoid arthritis. A Clinician's perspective. Immunopharmacology. 2000 May;47(2-3):259–271
  20. Furst DE, Breedveld FC, Burmester GR, et al. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). Annals of the Rheumatic Diseases. 2000 Nov;59(supplement 1):i1–i2
  21. Silman A, Klareskog L, Breedveld F, et al. Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological Compounds. Annals of the Rheumatic Diseases. 2000 Jun;59(6):419–420
  22. Silman A, Symmons D, Scott DG, Griffiths I. British Society for Rheumatology Biologics Register. Annals of the Rheumatic Diseases. 2003 Nov;62(supplement 2):ii28–ii29
  23. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Annals of the Rheumatic Diseases. 2006 Jun;65(6):707–712
  24. Zink A, Listing J, Kary S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Annals of the Rheumatic Diseases. 2005 Sep;64(9):1274–1279
  25. Hetland ML, Unkerskov J, Ravn T, et al. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). Scandinavian Journal of Rheumatology. 2005;34(1):40–44
  26. Saunders BM, Tran S, Ruuls S, et al. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. Journal of Immunology. 2005 Apr 15;174(8):4852–4859
  27. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annual Review of Immunology. 1996;14:397–440
  28. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis and Rheumatism. 1995 Apr;38(4):499–505
  29. Camussi G, Albano E, Tetta C, Bussolino F. The molecular action of tumor necrosis factor-alpha. European Journal of Biochemistry. 1991 Nov 15;202(1):3–14
  30. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995 Jun;2(6):561–572
  31. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infection and Immunity. 2001 Mar;69(3):1847–1855
  32. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis and Rheumatism. 2006 Jul 25;54(8):2368–2376
  33. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford). 2003 May;42(5):617–621
  34. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis and Rheumatism. 2006 Feb;54(2):628–634
  35. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis and Rheumatism. 2005 Feb;52(2):582–591
  36. Davis JC, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis and Rheumatism. 2003 Nov;48(11):3230–3236
  37. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Safety. 2004;27(5):307–324
  38. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. The New England Journal of Medicine. 2001 Oct 11;345(15):1098–1104
  39. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. The Lancet Infectious Diseases. 2003 Mar;3(3):148–155
  40. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clinical Infectious Diseases. 2004 May 1;38(9):1261–1265
  41. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clinical Infectious Diseases. 2004 Oct 15;39(8):1254–1255
  42. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?. Clinical Infectious Diseases. 2005 Aug 1;41(supplement 3):S199–S203
  43. Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor {alpha} therapy in rheumatoid arthritis: an update on safety. Annals of the Rheumatic Diseases. 2004 Dec;63(12):1538–1543
  44. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis and Rheumatism. 2005 Jun;52(6):1766–1772
  45. Deepe GS. Modulation of infection with Histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clinical Infectious Diseases. 2005 Aug 1;41(supplement 3):S204–S207
  46. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis and Rheumatism. 2002 Oct;46(10):2565–2570
  47. Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis and Rheumatism. 2003 Feb;48(2):319–324
  48. Filler SG, Yeaman MR, Sheppard DC. Tumor necrosis factor inhibition and invasive fungal infections. Clinical Infectious Diseases. 2005 Aug 1;41(supplement 3):S208–S212
  49. Seddik M, Melliez H, Seguy D, et al. Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflammatory Bowel Diseases. 2005 Jun;11(6):618–620
  50. De Rosa FG, Shaz D, Campagna AC, et al. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?. Infection Control and Hospital Epidemiology. 2003 Jul;24(7):477–482
  51. Allendoerfer R, Deepe GS. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. Journal of Immunology. 1998 Jun 15;160(12):6072–6082
  52. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis and Rheumatism. 2004 Jun;50(6):1959–1966
  53. CDC. FoodNet Surveillance Report for 2004 (Final Report). Atlanta; 2006 Jun. http://www.cdc.gov/foodnet/annual/2004/Report.pdf. Last access July 2006.
  54. Hinshaw LB, Emerson TE, Taylor FB, et al. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. The Journal of Trauma. 1992 Oct;33(4):568–573
  55. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995 Mar 22;273(12):934–941
  56. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Critical Care Medicine. 1996 Sep;24(9):1431–1440
  57. Abraham E, Glauser MP, Butler T, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA. 1997 May 21;277(19):1531–1538
  58. Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Medicine. 1999 Jun;25(6):556–566
  59. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. The New England Journal of Medicine. 1996 Jun 27;334(26):1697–1702
  60. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine. 2001 Jul;29(7):1303–1310
  61. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism. 2004 Apr;50(4):1051–1065
  62. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675–681
  63. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. The Journal of Rheumatology. 2001 Jun;28(6):1238–1244
  64. Kling A, Mjorndal T, Rantapaa-Dahlqvist S. Sepsis as a possible adverse drug reaction in patients with rheumatoid arthritis treated with TNF alpha antagonists. Jcr-Journal of Clinical Rheumatology. 2004 Jun;10(3):119–122
  65. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis and Rheumatism. 2005 Apr;52(4):1227–1236
  66. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism. 2005 Oct;52(10):3279–3289
  67. Baghai M, Osmon DR, Wolk DM, et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clinic Proceedings. 2001 Jun;76(6):653–656
  68. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis and Rheumatism. 2003 Nov;48(11):3013–3022
  69. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA. 1993 Oct 20;270(15):1826–1831
  70. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis and Rheumatism. 2002 Jun;46(6):1443–1450
  71. Vestergaard C, Johansen C, Otkjaer K, et al. Tumor necrosis factor-alpha-induced CTACK/CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor kappaB. Cytokine. 2005 Jan 21;29(2):49–55
  72. Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infectious Disease Clinics of North America. 2003 Jun;17(2):227–241
  73. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of TNF inhibitors in rheumatoid arthritis in an observational cohort study - comparison of patients according to their eligibility for major randomised clinical trials. Arthritis and Rheumatism. 2006 Nov;54(11):3399–3407
  74. Nicolle LE. Asymptomatic bacteriuria: when to screen and when to treat. Infectious Disease Clinics of North America. 2003 Jun;17(2):367–394
  75. Sipsas NV, Papaparaskevas J, Stefanou I, et al. Septic arthritis due to Roseomonas mucosa in a rheumatoid arthritis patient receiving infliximab therapy. Diagnostic Microbiology and Infectious Disease. 2006 Aug;55(4):343–345
  76. Netea MG, Radstake T, Joosten LA, et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis and Rheumatism. 2003 Jul;48(7):1853–1857
  77. Wilson MG, Kelley K, Thornhill TS. Infection as a complication of total knee-replacement arthroplasty. Risk factors and treatment in sixty-seven cases. The Journal of Bone and Joint Surgery. American Volume. 1990 Jul;72(6):878–883
  78. Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis and Rheumatism. 2006 Apr 15;55(2):333–337

PII: S1521-6942(06)00114-8

doi: 10.1016/j.berh.2006.08.010

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 6 , Pages 1181-1195 , December 2006

Article Tools